Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study

S Y Ryu, M H Kim, B H Nam, T S Lee, E S Song, C Y Park, J W Kim, Y B Kim, H S Ryu, S Y Park, K T Kim, C H Cho, C Lee, S M Kim, B G Kim, D S Bae, Y T Kim, J-H Nam, S Y Ryu, M H Kim, B H Nam, T S Lee, E S Song, C Y Park, J W Kim, Y B Kim, H S Ryu, S Y Park, K T Kim, C H Cho, C Lee, S M Kim, B G Kim, D S Bae, Y T Kim, J-H Nam

Abstract

Background: In this study, we sought to identify a criterion for the intermediate-risk grouping of patients with cervical cancer who exhibit any intermediate-risk factor after radical hysterectomy.

Methods: In total, 2158 patients with pathologically proven stage IB-IIA cervical cancer with any intermediate-risk factor after radical hysterectomy were randomly assigned to two groups, a development group and a validation group, at a ratio of 3 : 1 (1620 patients:538 patients). To predict recurrence, multivariate models were developed using the development group. The ability of the models to discriminate between groups was validated using the log-rank test and receiver operating characteristic (ROC) analysis.

Results: Four factors (histology, tumour size, deep stromal invasion (DSI), and lymphovascular space involvement (LVSI)) were significantly associated with disease recurrence and included in the models. Among the nine possible combinations of the four variables, models consisting of any two of the four intermediate-risk factors (tumour size ≥3 cm, DSI of the outer third of the cervix, LVSI, and adenocarcinoma or adenosquamous carcinoma histology) demonstrated the best performance for predicting recurrence.

Conclusion: This study identified a 'four-factor model' in which the presence of any two factors may be useful for predicting recurrence in patients with cervical cancer treated with radical hysterectomy.

Figures

Figure 1
Figure 1
The ROC curve analysis for recurrence confirmed that Model 2 performed better than the Classic and GOG criteria (A) and other models (B). Abbreviations: CI=confidence interval; H0=null hypothesis; Obs=observed; ROC=receiver operating characteristic.

References

    1. Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health. 2012;21:1031–1037.
    1. Bansal N, Herzog TJ, Shaw RE, Burke WM, Deutsch I, Wright JD.2009Primary therapy for early-stage cervical cancer: radical hysterectomy vs radiation Am J Obstet Gynecol 201485e1–e9.
    1. Chang SJ, Bristow RE, Ryu HS. A model for prediction of parametrial involvement and feasibility of less radical resection of parametrium in patients with FIGO stage IB1 cervical cancer. Gynecol Oncol. 2012;126:82–86.
    1. Delgado G, Bundy BN, Fowler WC, Jr, Stehman FB, Sevin B, Creasman WT, Major F, DiSaia P, Zaino R. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989;35:314–320.
    1. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990;38:352–357.
    1. Eifel PJ, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995;59:38–44.
    1. Farley JH, Hickey KW, Carlson JW, Rose GS, Kost ER, Harrison TA. Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early-stage, cervical carcinoma. Cancer. 2003;97:2196–2202.
    1. Fuller AF, Elliott N, Kosloff C, Hoskins WJ, Lewis JL., Jr Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix. Gynecol Oncol. 1989;33:34–39.
    1. Garg G, Shah JP, Toy EP, Christensen C, Deppe G, Asaad R, Morris RT. Stage IIA1 vs stage IIA2 cervical cancer: does the new staging criteria predict survival. Int J Gynecol Cancer. 2011;21:711–716.
    1. Huang YT, Wang CC, Tsai CS, Lai CH, Chang TC, Chou HH, Lee SP, Hong JH. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84:420–427.
    1. Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol. 2011;120:439–443.
    1. Mabuchi S, Okazawa M, Matsuo K, Kawano M, Suzuki O, Miyatake T, Enomoto T, Kamiura S, Ogawa K, Kimura T. Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma vs squamous cell carcinoma. Gynecol Oncol. 2012;127:114–120.
    1. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Further stratification of risk groups in patients with lymph node metastasis after radical hysterectomy for early-stage cervical cancer. Gynecol Oncol. 2010;117:53–58.
    1. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix. Br J Cancer. 2010;102:1692–1698.
    1. Peters WA, 3rd, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W, Jr, Alberts DS. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–1613.
    1. Rogers L, Siu SS, Luesley D, Bryant A, Dickinson HO. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev. 2012. p. CD007583.
    1. Rudtanasudjatum K, Charoenkwan K, Khunamornpong S, Siriaunkqul S. Impact of histology on prognosis of patients with early-stage cervical cancer treated with radical surgery. Int J Gynaecol Obstet. 2011;115:183–187.
    1. Ryu SY, Park SI, Nam BH, Cho CK, Kim K, Kim BJ, Kim MH, Choi SC, Lee ED, Lee KH. Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors. Int J Radiat Oncol Biol Phys. 2011;79:794–799.
    1. Samlal RA, van der Velden J, Ten Kate FJ, Schilthuis MS, Hart AA, Lammes FB. Surgical pathologic factors that predict recurrence in stage IB and IIA cervical carcinoma patients with negative pelvic lymph nodes. Cancer. 1997;80:1234–1240.
    1. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy vs no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73:177–183.
    1. Shibata K, Kajiyama H, Yamamoto E, Terauchi M, Ino K, Nomura S, Nawa A, Kawai M, Kikkawa F. Effectiveness of preoperative concurrent chemoradiation therapy (CCRT) for locally advanced adenocarcinoma of cervix. Eur J Surg Oncol. 2009;35:768–772.
    1. Turan T, Yildirim BA, Tulunay G, Boran N, Kose MF. Prognostic effect of different cut-off values (20 mm, 30 mm and 40 mm) for clinical tumour size in FIGO stage IB cervical cancer. Surg Oncol. 2010;19:106–113.
    1. Van de Putte G, Lie AK, Vach W, Baekelandt M, Kristensen GB. Risk grouping in stage IB squamous cell cervical carcinoma. Gynecol Oncol. 2005;99:106–112.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere